AXBIO
安序源
AXBIO (安序源) is a fourth-generation nanopore gene-sequencing company that raised nearly $100 million in a Series B round in mid-2022, led by AstraZeneca-CICC Healthcare Industry Fund and Yunfeng Capital, with participation from CBC Group, SDIC Capital and others . By mid-2023 it had announced a strategic partnership with Juyun Gene and launched its fourth-generation nanopore gene-sequencing platform . The company is a portfolio holding of 5Y Capital (五源资本), which has featured its milestones in monthly newsletters alongside other biotech investments such as Syneron Bio .
AI-generated — may contain errors, please verify.
Coverage
June, the World's Childhood | 5Y News Monthly
The big news from last month.
五源资本·May, Where Hope Springs Eternal | 5Y News Monthly
The big news from last month.
五源资本·July: Seeking Vast Possibilities | 5Y News Monthly
The big news from last month.
五源资本·5Y News | Axbio Closes Nearly $100M Series B Funding Round
Make faster, more accessible, ultra-low-cost sequencing products available to the life sciences and healthcare industries.
五源资本·
